Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Real-time Estimate Cboe BZX
Other stock markets
 02:03:53 2024-05-24 pm EDT 		5-day change 1st Jan Change
4.09 USD -0.24% Intraday chart for Vistagen Therapeutics, Inc. -7.88% -20.43%
May. 23 Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference CI
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6
MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target
MT
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating
MT
Rate hike fears return with a vengeance
Our Logo
Maxim Downgrades VistaGen Therapeutics to Hold From Buy
MT
Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8
MT
William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform
MT
VISTAGEN THERAPEUTICS : Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target
MT
VISTAGEN THERAPEUTICS : Jefferies Starts VistaGen Therapeutics at Buy with $6 Price Target
MT
VISTAGEN THERAPEUTICS : William Blair Upgrades VistaGen Therapeutics to Outperform From Market Perform
MT
VISTAGEN THERAPEUTICS : Maxim Adjusts Price Target on VistaGen Therapeutics to $5 From $3, Reiterates Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. News Vistagen Therapeutics, Inc.
  5. Analyst Reco.